1. Home
  2. TNET vs EWTX Comparison

TNET vs EWTX Comparison

Compare TNET & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriNet Group Inc.

TNET

TriNet Group Inc.

HOLD

Current Price

$68.75

Market Cap

3.1B

ML Signal

HOLD

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

HOLD

Current Price

$44.17

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNET
EWTX
Founded
1988
2017
Country
United States
United States
Employees
2700
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.7B
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
TNET
EWTX
Price
$68.75
$44.17
Analyst Decision
Hold
Buy
Analyst Count
5
6
Target Price
$65.80
$39.00
AVG Volume (30 Days)
421.7K
1.1M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
2.57%
N/A
EPS Growth
N/A
N/A
EPS
3.05
N/A
Revenue
$5,010,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.30
N/A
P/E Ratio
$22.99
N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.67
$13.53
52 Week High
$73.08
$48.40

Technical Indicators

Market Signals
Indicator
TNET
EWTX
Relative Strength Index (RSI) 61.08 55.97
Support Level $55.63 $37.50
Resistance Level $73.08 $44.93
Average True Range (ATR) 3.60 2.17
MACD -0.49 0.11
Stochastic Oscillator 51.58 75.25

Price Performance

Historical Comparison
TNET
EWTX

About TNET TriNet Group Inc.

Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Share on Social Networks: